There was a significant decrease in plasma IgG levels for CD25‐MUC1‐VEGFR1 combinations in patients with either adenocarcinoma or squamous cell carcinoma while a significant decrease in plasma IgG levels for POU5F1 in patients with adenocarcinoma (Table 6). This evidence concerns the gene MUC1 and squamous cell carcinoma.